Literature DB >> 21389256

Conventional dendritic cells are required for the activation of helper-dependent CD8 T cell responses to a model antigen after cutaneous vaccination with lentiviral vectors.

Hugh D Goold1, David Escors, Thomas J Conlan, Ronjon Chakraverty, Clare L Bennett.   

Abstract

Cutaneous vaccination with lentiviral vectors generates systemic CD8 T cell responses that have the potential to eradicate tumors for cancer immunotherapy. However, although s.c. immunization with <1 million lentiviral particles clearly primes cytotoxic T cells, vaccination with much higher doses has routinely been used to define the mechanisms of T cell activation by lentiviral vectors. In particular, experiments to test presentation of lentiviral Ags by dendritic cells (DC) require injection of high viral titers, which may result in aberrant transduction of different DC populations. We exploited inducible murine models of DC depletion to investigate which DC prime the lentiviral response after s.c. immunization with low doses of lentiviral particles. In this article, we demonstrate that conventional DC are required to present Ag to CD8 T cells in draining lymph nodes. Langerhans cells are not required to activate the effector response, and neither Langerhans cells nor plasmacytoid DC are sufficient to prime Ag-specific T cells. Immunization drives the generation of endogenous long-lived memory T cells that can be reactivated to kill Ag-specific targets in the absence of inflammatory challenge. Furthermore, lentiviral vaccination activates expansion of endogenous CD4 Th cells, which are required for the generation of effector CD8 T cells that produce IFN-γ and kill Ag-specific targets. Collectively, we demonstrate that after cutaneous immunization with lentiviral particles, CD4-licensed lymph node conventional DC present Ag to CD8 T cells, resulting in the generation of protective endogenous antitumor immunity that may be effective for cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21389256      PMCID: PMC3071788          DOI: 10.4049/jimmunol.1002529

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

1.  Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity.

Authors:  Christopher M Smith; Nicholas S Wilson; Jason Waithman; Jose A Villadangos; Francis R Carbone; William R Heath; Gabrielle T Belz
Journal:  Nat Immunol       Date:  2004-10-10       Impact factor: 25.606

2.  The role of skin-derived dendritic cells in CD8+ T cell priming following immunization with lentivectors.

Authors:  Karina Furmanov; Mazal Elnekave; Dan Lehmann; Bjorn E Clausen; Darrell N Kotton; Avi-Hai Hovav
Journal:  J Immunol       Date:  2010-03-31       Impact factor: 5.422

3.  Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors.

Authors:  M Dullaers; S Van Meirvenne; C Heirman; L Straetman; A Bonehill; J L Aerts; K Thielemans; K Breckpot
Journal:  Gene Ther       Date:  2006-04       Impact factor: 5.250

4.  Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization.

Authors:  Yukai He; Jiying Zhang; Cara Donahue; Louis D Falo
Journal:  Immunity       Date:  2006-05       Impact factor: 31.745

5.  Effect of a CD4-depleting antibody on the development of Cryptococcus neoformans-induced allergic bronchopulmonary mycosis in mice.

Authors:  Shikha Arora; Roderick A McDonald; Galen B Toews; Gary B Huffnagle
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 6.  Lentivirus as a potent and mechanistically distinct vector for genetic immunization.

Authors:  Yukai He; Louis D Falo
Journal:  Curr Opin Mol Ther       Date:  2007-10

7.  Compensatory role of Langerhans cells and langerin-positive dermal dendritic cells in the sensitization phase of murine contact hypersensitivity.

Authors:  Tetsuya Honda; Saeko Nakajima; Gyohei Egawa; Kouetsu Ogasawara; Bernard Malissen; Yoshiki Miyachi; Kenji Kabashima
Journal:  J Allergy Clin Immunol       Date:  2010-03-11       Impact factor: 10.793

8.  Modulation of human dendritic-cell function following transduction with viral vectors: implications for gene therapy.

Authors:  Peng H Tan; Sven C Beutelspacher; Shao-An Xue; Yao-He Wang; Peter Mitchell; James C McAlister; D Frank P Larkin; Myra O McClure; Hans J Stauss; Mary A Ritter; Giovanna Lombardi; Andrew J T George
Journal:  Blood       Date:  2005-01-25       Impact factor: 22.113

9.  Immunization with a lentivector that targets tumor antigen expression to dendritic cells induces potent CD8+ and CD4+ T-cell responses.

Authors:  Luciene Lopes; Marie Dewannieux; Uzi Gileadi; Ranbir Bailey; Yasuhiro Ikeda; Christopher Whittaker; Matthew P Collin; Vincenzo Cerundolo; Mizuki Tomihari; Kiyoshi Ariizumi; Mary K Collins
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

10.  Targeting dendritic cell signaling to regulate the response to immunization.

Authors:  David Escors; Luciene Lopes; Rongtuan Lin; John Hiscott; Shizuo Akira; Roger J Davis; Mary K Collins
Journal:  Blood       Date:  2008-01-07       Impact factor: 22.113

View more
  16 in total

1.  A TLR4 agonist synergizes with dendritic cell-directed lentiviral vectors for inducing antigen-specific immune responses.

Authors:  Liang Xiao; Jocelyn Kim; Matthew Lim; Bingbing Dai; Lili Yang; Steven G Reed; David Baltimore; Pin Wang
Journal:  Vaccine       Date:  2012-02-05       Impact factor: 3.641

2.  Monophosphoryl lipid A-induced activation of plasmacytoid dendritic cells enhances the anti-cancer effects of anti-PD-L1 antibodies.

Authors:  Wei Zhang; Seong-Min Lim; Juyoung Hwang; Srinivasan Ramalingam; Myunghee Kim; Jun-O Jin
Journal:  Cancer Immunol Immunother       Date:  2020-09-09       Impact factor: 6.968

3.  Immunoglobulin Fc fragment tagging allows strong activation of endogenous CD4 T cells to reshape the tumor milieu and enhance the antitumor effect of lentivector immunization.

Authors:  Yuan Hong; Yibing Peng; Haiyan Xiao; Michael Mi; David Munn; Yukai He
Journal:  J Immunol       Date:  2012-04-13       Impact factor: 5.422

4.  Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy.

Authors:  Therese Liechtenstein; Noemi Perez-Janices; Idoia Blanco-Luquin; Cleo Goyvaerts; Julia Schwarze; Ines Dufait; Alessio Lanna; Mark De Ridder; David Guerrero-Setas; Karine Breckpot; David Escors
Journal:  Oncoimmunology       Date:  2014-07-03       Impact factor: 8.110

5.  Harnessing alveolar macrophages for sustained mucosal T-cell recall confers long-term protection to mice against lethal influenza challenge without clinical disease.

Authors:  D C Macdonald; H Singh; M A Whelan; D Escors; F Arce; S E Bottoms; W S Barclay; M Maini; M K Collins; W M C Rosenberg
Journal:  Mucosal Immunol       Date:  2013-05-29       Impact factor: 7.313

6.  PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells.

Authors:  Katarzyna Karwacz; Christopher Bricogne; Douglas MacDonald; Frederick Arce; Clare L Bennett; Mary Collins; David Escors
Journal:  EMBO Mol Med       Date:  2011-08-10       Impact factor: 12.137

7.  Lentiviral vectors for cancer immunotherapy and clinical applications.

Authors:  Therese Liechtenstein; Noemi Perez-Janices; David Escors
Journal:  Cancers (Basel)       Date:  2013-09       Impact factor: 6.639

8.  MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY.

Authors:  Therese Liechtenstein; Ines Dufait; Alessio Lanna; Karine Breckpot; David Escors
Journal:  Immunol Endocr Metab Agents Med Chem       Date:  2012-09

9.  A nonintegrative lentiviral vector-based vaccine provides long-term sterile protection against malaria.

Authors:  Frédéric Coutant; Raul Yusef Sanchez David; Tristan Félix; Aude Boulay; Laxmee Caleechurn; Philippe Souque; Catherine Thouvenot; Catherine Bourgouin; Anne-Sophie Beignon; Pierre Charneau
Journal:  PLoS One       Date:  2012-11-02       Impact factor: 3.240

10.  4-1BB ligand activates bystander dendritic cells to enhance immunization in trans.

Authors:  Douglas C Macdonald; Alastair Hotblack; Saniath Akbar; Gary Britton; Mary K Collins; William C Rosenberg
Journal:  J Immunol       Date:  2014-10-10       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.